Atlas company financials

VERTEX PHARMACEUTICALS INC / MA

Standardized 18-year financial series for VERTEX PHARMACEUTICALS INC / MA, built from filing-derived source data and exposed in JSON, CSV, and XLSX so it can feed iterFact artifacts or analyst workflows without hand-entering the numbers.

United StatesCIK 0000875320FY2008 → FY2025

Open JSON Download CSV Download XLSX Quarterly JSON Summary JSON Filing index

Latest fiscal year

FY2025

Revenue

$12B

Adjusted EBITDA

—

Net result

$4B

Net financial debt

—

Latest source: FY2025 filing · published data snapshot generated April 26, 2026

Phase 2 summary

Latest quarter, TTM, and growth are now pre-computed for chat and templates.

Latest quarter revenue

$3.1B

TTM revenue

$11.6B

TTM free cash flow

—

Latest quarter net result

$1.1B

Quarterly coverage: 51 periods · latest quarter FY2025-Q3 · TTM revenue growth 12.3%.

What this gives you

A proof-of-concept company data surface, not a dead PDF shelf.

The same standardized payload behind this page is exposed through downloadable CSV and XLSX files plus a stable JSON route. That makes it usable as a live input to iterFact templates, a spreadsheet handoff, or a future API surface without re-normalizing the source documents again.

Source audit

Official links first, raw iterFact payloads right next to them.

Official sources

SEC EDGAR companyfacts
comparative · vertex-pharmaceuticals-inc-ma-fy2008 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2011-02-17 · Retrieved: 2026-04-26T11:39:19.359841+00:00
SEC EDGAR companyfacts
us-gaap:NetIncomeLoss · us gaap companyfacts · comparative · vertex-pharmaceuticals-inc-ma-fy2009 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2012-02-22 · Retrieved: 2026-04-26T11:39:19.359841+00:00
SEC EDGAR companyfacts
us-gaap:CostOfGoodsSold · us gaap companyfacts · comparative · vertex-pharmaceuticals-inc-ma-fy2010 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2013-03-01 · Retrieved: 2026-04-26T11:39:19.359841+00:00
SEC EDGAR companyfacts
primary · vertex-pharmaceuticals-inc-ma-fy2013 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2014-02-11 · Retrieved: 2026-04-26T11:39:19.359841+00:00
SEC EDGAR companyfacts
primary · vertex-pharmaceuticals-inc-ma-fy2014 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2015-02-13 · Retrieved: 2026-04-26T11:39:19.359841+00:00

Ten-year series

Headline company financials by fiscal year

Fiscal year	Revenue	Adj. EBITDA	EBIT	Net result	Op. cash flow	Capex	Net debt	Status
FY2008	176M	—	-463M	—	-226M	-32M	—	comparative annual fact carried from later 10k · missing accounts receivable · missing adjusted ebitda · missing cost of revenue · missing current assets · missing current liabilities · missing gross profit · missing inventory · missing net financial debt · missing net result · missing total assets
FY2009	102M	—	-614M	-642M	-428M	-23M	—	comparative annual fact carried from later 10k · missing adjusted ebitda · missing cost of revenue · missing gross profit · missing inventory · missing net financial debt
FY2010	143M	—	-696M	-755M	-635M	-38M	—	missing adjusted ebitda · missing gross profit · missing inventory · missing net financial debt
FY2011	1B	—	114M	30M	144M	-35M	—	missing adjusted ebitda · missing gross profit · missing net financial debt
FY2012	2B	—	2M	-107M	268M	-71M	—	missing adjusted ebitda · missing gross profit · missing net financial debt
FY2013	1B	—	-903M	-445M	-52M	-51M	—	missing adjusted ebitda · missing gross profit · missing interest expense · missing net financial debt
FY2014	580M	—	-692M	-739M	-513M	-51M	—	missing adjusted ebitda · missing gross profit · missing interest expense · missing net financial debt
FY2015	1B	—	-467M	-556M	-365M	-45M	—

Filing provenance